Alnylam Pharmaceuticals reported $40.27M in Interest Expense on Debt for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alexion Pharmaceuticals ALXN:US $ 27.1M 0.6M
Alnylam Pharmaceuticals ALNY:US $ 40.27M 6.86M
Amgen AMGN:US $ 296M 15M
Arena Pharmaceuticals ARNA:US $ 1.03M 0.02M
Biocryst Pharmaceuticals BCRX:US $ 14.12M 0.62M
Biomarin Pharmaceutical BMRN:US $ 3.87M 0.05M
Dicerna Pharmaceuticals DRNA:US $ 0M 0M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
Intercept Pharmaceuticals ICPT:US $ 14.1M 1.51M
IONIS PHARMACEUT IONS:US $ 2.34M 0.02M
Moderna Inc MRNA:US 4M 1000K
Neurocrine Biosciences NBIX:US $ 6.6M 0.4M
Novartis NVS:US $ 202M 1M
Ptc Therapeutics PTCT:US $ 21.8M 0.76M
Regeneron Pharmaceuticals REGN:US $ 14.2M 0.2M
Sarepta Therapeutics SRPT:US $ 16M 0.16M
Vertex Pharmaceuticals VRTX:US $ 15.26M 0.22M
YTE INCY:US $ 0.44M 0.08M